Surgery Effective for Thoracic Ossification of Posterior Longitudinal Ligament
By Elana Gotkine HealthDay Reporter
THURSDAY, Aug. 22, 2024 -- For patients with thoracic ossification of the posterior longitudinal ligament (T-OPLL), surgical treatment is effective for improving neurological function, quality of life (QoL), and pain management during a 10-year period, according to a study published online Aug. 5 in the Journal of Bone & Joint Surgery.
Sadayuki Ito, M.D., Ph.D., from the Nagoya University Graduate School of Medicine in Japan, and colleagues retrospectively examined 51 patients followed for ≥10 years after posterior decompression and corrective fusion surgery for T-OPLL to assess clinical, functional, and QoL outcomes.
The researchers found a significant improvement in the Japanese Orthopaedic Association score from preoperatively to two years postoperatively (3.7 to 7.9); thereafter, the score remained stable. The mean EuroQol-5 Dimension-5 Level score improved from 0.53 to 0.68 from preoperatively to 10 years postoperatively. For both back and leg pain, the numerical rating scale scores decreased from 5.4 to 3.5 and from 4.0 to 3.0, respectively, from preoperatively to 10 years postoperatively. Kyphotic angles and ossification areas changed, with no significant progression after two years. Overall, 14 patients (27.5 percent) experienced postoperative complications; eight (15.7 percent) required reoperation: six and two in the perioperative period and later, respectively. Additional surgeries for conditions including lumbar spinal canal stenosis and cervical OPLL were performed for four of the patients (7.8 percent). In all cases with postoperative complications or additional surgery, physical function remained stable over the decade.
"These complications and interventions did not substantially detract from the overall QoL improvement," the authors write.
Abstract/Full Text (subscription or payment may be required)
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
![](/img/logo/vendor/healthday-logo.png)
© 2024 HealthDay. All rights reserved.
Posted August 2024
Read this next
Outcomes Similar for Neoadjuvant ICI-Based Therapy, Upfront Surgery for Liver Cancer
THURSDAY, Aug. 22, 2024 -- Patients treated with neoadjuvant immune checkpoint inhibitor (ICI)-based therapy for hepatocellular carcinoma (HCC) have higher-risk disease features...
Study Quantifies COVID-19-Linked Deficit in Arthroplasties in the U.K.
THURSDAY, Aug. 15, 2024 -- The COVID-19-induced deficit in arthroplasty procedures is equivalent to 71.6 percent of a year of normal expected operating activity, according to a...
Problematic Pharmaceutical Opioid Use Common in Noncancer Pain
THURSDAY, Aug. 15, 2024 -- For individuals with chronic noncancer pain (CNCP) treated with opioid analgesics, problematic pharmaceutical opioid use (POU) is common, according to a...
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.